This Dividend King Just Announced Great News for Investors

Abbott Laboratories, known as a Dividend King for increasing its dividend for over 50 consecutive years, recently shared positive updates on its financial performance. The company's sales grew 7% year-over-year, with medical devices and pharmaceuticals being the primary growth drivers. Abbott's medical device segment, specifically its FreeStyle Libre continuous glucose monitoring systems, showed a 6.7% increase in sales.

The company also announced that it will spin off its nutrition business into a stand-alone entity, potentially leading to better long-term growth and higher margins. Abbott's decision to spin off the nutrition business may help it avoid legal and regulatory hurdles that have negatively impacted the segment's sales in recent years.

Additionally, Abbott's acquisition of Exact Sciences, a company specializing in cancer diagnostics, strengthens its position in the growing cancer diagnostic market.